Following in the footsteps of SABCS 2022: top 16 early breast cancer studies that could change our clinical practice: A review

Kolyadina, I. V.

doi:10.26442/18151434.2023.1.202053

J. Mod. Onco.

2023

DOI: 10.26442/18151434.2023.1.202053

|View full text |Cite

Following in the footsteps of SABCS 2022: top 16 early breast cancer studies that could change our clinical practice: A review

I. V. Kolyadina

Abstract: A review of the studies presented at the SABCS 2022 conference on the treatment of breast cancer (BC) has been carried out; 16 of the most exciting and significant works reported at oral or poster sessions have been identified. Data from large randomized and population-based studies were presented, including TAM-01 (the role of adjuvant therapy with 5 mg tamoxifen for in situ cancer), six studies on the surgical treatment of early breast cancer, including a meta-analysis to assess the effect of surgery extent … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite3

Independent0

Authors

Journals

Cited by 3 publications

References 25 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Clinical and radiological efficacy of a new conservative treatment for fibrocystic disease

Shabaev,

Kolyadina,

Blagovestnov

et al. 2024

Opuholi ženskoj reproduktivnoj sistemy

Self Cite

View full text Add to dashboard Cite

Background. Long-lasting dyshormonal breast diseases in women represent a risk factor for breast cancer, especially in patients with atypia. Clinical manifestations of fibrocystic breast disease (FBD) and mastopathy, including high-intensity pain cause psychoemotional discomfort and reduce the quality of life of women. The search for effective management strategies for mastopathy with an antiproliferative effect is highly relevant.Aim. To assess clinical and radiological efficacy of a new conservative treatment for FBD, “Evening primrose oil” administered orally for 6 months in women with symptomatic FBD.Materials and methods. This randomized, blind, placebo-controlled trial included 144 patients with clinical FBD manifestations (pain and tension in the breast). Patients were randomly assigned to one of the two treatment groups. Women in group I received “Evening primrose oil”, whereas women in group II received placebo (ascorbic acid) for 6 months. We measured the dynamics of radiological findings (at mammography and ultrasound examination) in the breast before and after treatment, as well as pain intensity using the visual-analog scale.Results. Patients in group I with all types of FBD (diffuse mastopathy, nodular, and mixed forms) demonstrated positive dynamics and BI-RADS category downgrading within 6 months. In the placebo group, the examination after 6 months demonstrated no significant changes in the breast and no BI-RADS category downgrading among women with diffuse mastopathy. Some patients with nodular and mixed FBD receiving placebo had negative dynamics after 6 months (as demonstrated by mammography and ultrasound examination; BI-RADS category upgraded from II to III, p<0.01). Patients receiving “Evening primrose oil” also showed positive dynamics in their clinical manifestations, including decreased breast pain (from 7.8 to 1.8 on the visual analog scale). By contrast, patients receiving placebo had no changes in their breast pain intensity after 6 months (from 7.3 to 7.1 on the visual analog scale), which resulted in poorer psychoemotional state in 55.6 % of women.Conclusion. Our new treatment strategy for FBD patients with clinical and radiological manifestations in the breast demonstrated high efficiency and can be implemented into routine clinical practice.

show abstract

Clinical and radiological efficacy of a new conservative treatment for fibrocystic disease

Shabaev,

Kolyadina,

Blagovestnov

et al. 2024

Opuholi ženskoj reproduktivnoj sistemy

Self Cite

View full text Add to dashboard Cite

show abstract

Risk factors for breast cancer in patients with benign breast diseases: a 10-year observational study

Shabaev,

Kolyadina,

Blagovestnov

et al. 2024

Opuholi ženskoj reproduktivnoj sistemy

Self Cite

View full text Add to dashboard Cite

Aim. To assess risk factors for breast cancer in a large population of women with benign breast dysplasia (BBD) followed up for a long time.Materials and methods. This retrospective study included 504 women with BBD followed up for 10 years. Study participants were divided into two groups: 1) BBD patients who did not develop breast cancer within 10 years (n = 261); 2) BBD patients who developed breast cancer within 10 years (n = 243). We conducted comprehensive retrospective analysis of demographic, clinical, and laboratory characteristics, as well as treatment details for BBD. Patient age varied between 39 and 49 years. The ten-year follow-up interval was chosen to perform adequate comparison of the groups. The differences were considered significant at p <0.05.Results. The main difference between the two groups was related to conservative treatment for BBD and its duration. Almost all (93.4 %) patients in the group without breast cancer received some conservative treatment for BBD for 78.0 ± 1.7 months, whereas among those who developed breast cancer, only 37.4 % received conservative therapy for 15.0 ± 0.8 months (p <0.001). Other significant risk factors for breast cancer in group 2 included obesity, gynecological pathology, long-term stress, and no surgical treatment for benign breast changes (p <0.001). The analysis of laboratory parameters demonstrated significantly higher levels of prolactin in patients who developed breast cancer (31 % versus 13 %; p <0.001).Conclusion. Potential risk factors for breast cancer in BBD patients include overweight, benign gynecological diseases, elevated prolactin, and long-term stress. Timely diagnosis and treatment of BBD and elimination of the abovementioned factors can significantly reduce the probability of breast cancer.

show abstract

Hereditary forms of breast malignant neoplasms: prognosis, screening and prevention. A review

Sultanbaev,

Kolyadina,

Gilyazova

et al. 2024

J. Mod. Onco.

Self Cite

View full text Add to dashboard Cite

Carriers of germinal mutations are at high risk of developing malignant neoplasms, characterized by an early age of manifestation, an aggressive course, and a high risk of recurrence. The wide introduction of medical genetic testing in the target population of potential carriers of germinal mutations will optimize primary prevention, screening, and treatment approaches. Primary prevention (removal of target organs) with BRCA½ mutation carriers should be based on the benefit-risk ratio; the development of screening programs should take into account the early age of disease manifestation, high breast density in young women, and the predominance of aggressive biological subtypes of the disease, which requires more intensive screening programs in this population. Pathogenetic adjuvant therapy with olaparib significantly reduces the risk of recurrence and death in patients with early BRCA - associated breast cancer and can also help prevent the development of second malignant neoplasms.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Following in the footsteps of SABCS 2022: top 16 early breast cancer studies that could change our clinical practice: A review

Cited by 3 publications

References 25 publications

Clinical and radiological efficacy of a new conservative treatment for fibrocystic disease

Clinical and radiological efficacy of a new conservative treatment for fibrocystic disease

Risk factors for breast cancer in patients with benign breast diseases: a 10-year observational study

Hereditary forms of breast malignant neoplasms: prognosis, screening and prevention. A review

Contact Info

Product

Resources

About